The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.
The FDA’s decision to approve the drug, siding with industry and patient advocates, raises new questions about whether it is lowering its burden of proof for drugmakers.
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться